FDA, FTC take aim at abuse of restricted drug programs
Last year, generic drugmakers filed 150 complaints with the Food and Drug Administration that branded drug manufacturers were misusing the agency’s regulations to block them from offering cheaper alternatives for some...
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: